Introduction 42

Many chemical compounds have recently been synthesized and characterized to develop 43
new drug candidates in pharmaceutical industries. However, more than 40% of these 44 compounds have been terminated due to poor dissolution and/or biomembrane permeability 45 (Prentis et al., 1988; Venkatesh and Lipper, 2000) . Poorly water-soluble compounds have 46 been detected not only in medicines, but also in dietary and cosmetic supplements. 47 5 were obtained from Tokyo Chemical Industry (Tokyo, Japan). β-CD, 6-methyl diosgenin, and 90 other chemicals were obtained from Wako Pure Chemical Industries (Osaka, Japan). 91 92
Preparation of liquid crystals 93
LC was formed using GMO or PHY and an equal or greater volume of water, and 94 involved a transition from the lamella phase to the hexagonal phase, and finally to the cubic 95 phase by heating (Lee et al., 2009 ). To determine the solubility of diosgenin in lipids, each 96 lipid was added to a tube with an excess amount of diosgenin. The mixture was heated at 37°C 97 in a heating block to facilitate solubilization using a vortex mixer. Mixtures were shaken in a 98 thermo-controlled incubator at 37°C for 2 h. After reaching equilibrium, each tube was 99 centrifuged at 15,000 ×g for 5 min and the supernatant was collected. After dilution, the 100 content of diosgenin was determined using a liquid chromatography mass spectrometry (LCMS) 101 system. Separation was achieved by an MXY01-01 (Michrom Biosources Inc., CA, U.S.A.) 102 with a TSK gel ODS-100V column (2.0×50 mm, 3 µm) (TOSOH, Tokyo, Japan) at room 103 temperature. The mobile phase consisted of methanol (90%) and H 2 O (10%) containing 10 104 mM ammonium acetate. The flow rate was set to 150 µL/min and detection was performed 105 using an LCQ DECA XP Plus mass spectrometer (Thermo Fisher Scientific Inc., MA, U.S.A.). 106
Self-assembly LCs were prepared by dissolving diosgenin in each lipid at 5 mg/mL by heating 107 at 70°C. 108 109
SAXS measurement 110
Equal volumes of water and self-assembly LC were mixed prior to measurements being 111 taken. These samples were heated at 70°C, and mixed to homogenization using a vortex mixer. 112 SAXS measurements were performed on a NANO-Viewer (Rigaku) with PILATUS 100K/RL6 2D detector. The X-ray source was Cu Kα radiation, wavelength 1.54 Å, operating at 45 kV 114 and 110 mA. The sample-to-detector distance was chosen to be 375 mm. Each sample was 115 placed between polyether ether ketone membranes and exposed for 10 min. 116 117
Dispersibility of LC 118
Dispersed LC was prepared by adding 10-fold of water to self-assembly LC. The 119 mixture was heated on a heating block at 70°C, and shaken using a vortex mixer. These 120 samples were centrifuged at 15,000 ×g for 5 min, and the water phase was collected. Samples 121
were diluted 1000-fold in water prior to measurements being taken. Particle diameters and 122 dispersion were measured by dynamic light scattering measurements on a Nano-ZS ZEN 3600 123
Zetasizer (Malvern, Worcestershire, UK) with water. 124 125
Solubility study 126
In the solubility study, 10-fold of water or 4 mM β-CD solution were added to 127 self-assembly LC, and mixed at 37°C for 5 days. These samples were centrifuged at 15,000×g 128 for 5 min, and the water phases were collected. The contents of diosgenin and each lipid were 129 determined using an LCMS system after filtration with a 0.2 µm membrane filter (ADVANTEC, 130
Tokyo, Japan) and dilution. 131 132
Animals 133
Male Wistar rats (200 to 250 g) were provided from Japan SLC (Hamamatsu, Shizuoka, 134 Japan). Animals were housed under a 12 h light and dark cycle in a temperature-controlled 135 room (23 ± 2°C). They had free access to food and water. The animal care protocol was 136 approved by the Animal Care and Use Committee of Josai University (Saitama, Japan).
138
Pharmacokinetic studies 139
Intravenous and oral administration studies were performed to compare the 140 pharmacokinetic parameters of diosgenin and its LC. Rats were fasted from at least 12 h prior 141 dosing to 4 h after dosing. In the intravenous administration protocol, diosgenin was dissolved 142 in saline containing 1% HCO-60, and 121 µg/kg (body weight) of diosgenin was injected into 143 the tail vein. For oral administration, a diosgenin suspension of 5 mg/mL or self-assembly LC 144 formulation containing an equivalent amount of diosgenin was prepared and administered at a 145 dose of 2 mL/kg (body weight). Diosgenin was suspended in saline containing 1% HCO-60. 146
Self-assembly LC was prepared by dissolving diosgenin in PHY or GMO. In the LC group, 147 self-assembly LC and equal amounts of water or β-CD solution (24 mM) were simultaneously 148 administrated. Blood was collected from the tail vein into heparinized tubes at times ranging 149 from 0 to 96 h, and was immediately separated by centrifugation. In a previous study, skin 150 levels of diosgenin peaked 6 h after its oral administration (Okawara et al., 2013). Skin 151 samples were taken from the entire abdomen 6 h after the oral administration. Each sample 152 was stored at -30°C until analyzed. 153 154
Analytical procedure 155
6-methyl diosgenin was used as an internal standard to assess diosgenin levels in plasma 156 and skin samples. Samples were added to methanol and extraction was achieved by sonication 157 for 20 min at 37°C. These samples were centrifuged at 15,000 × g for 5 min and the 158 supernatants were collected. The content of diosgenin was determined by an LCMS system 159 with a Tosoh TSK gel ODS-100V column (2.0×50 mm, 3 µm) at room temperature. 160 161 8
Pharmacokinetics and statistical analysis 162
Pharmacokinetics analysis was performed with nonlinear least-squares fitting. The area 163 under the plasma concentration-time curve (AUC) was calculated using the linear trapezoidal 164 rule. The absolute bioavailability was determined as AUCpo/AUCiv, using mean AUC values 165 for oral and intravenous doses. Tukey's multiple comparison tests was used to assess the 166 significance of differences between groups. A p value of less than 0.05 was considered 167 significant. 168 9
Results 170
SAXS measurements 171
The phase behavior of LCs made from GMO or PHY was confirmed by SAXS 172 measurements. Representatives of the SAXS profiles of LCs are shown in Figure 1 . SAXS 173 curves revealed the presence of a hexagonal phase (with reflections spaced at √1, √3, and √4; 174 
Dispersibility of LC 180
The particle diameter and dispersion of LCs were measured to confirm their conditions in the 181 gastric and intestinal tract. The particle diameters of LCs made from GMO and PHY are listed 182 in Table 1 . Each particle diameter of LCs was nearly 100-200 nm and its distribution in water 183 remained unchanged in the presence of diosgenin. PHY LC showed larger diameter than 184 GMO LC both with and without diosgenin. Although the diameter of a particle of PHY 185 became small by diosgenin, it is unknown for details. 186 187
Solubility study 188
The solubility of diosgenin and lipids in water or β-CD solution are listed in Table 2 . 189
The solubility of diosgenin was increased by β-CD and GMO, whereas it was decreased by 190 PHY. It is suggested that the lower release of diosgenin was caused by PHY melting point 191 (70°C). More diosgenin was released from LCs in β-CD solution than in water. 192
Correspondingly, the solubilities of GMO and PHY in water were increased by β-CD. The time to reach the maximum plasma concentration (Tmax) of GMO LC was similar to that 201 of the suspension ( Fig. 2A) . However, the Tmax was significantly higher and Cmax was 202 significantly lower with PHY LC than with the diosgenin suspension (Fig. 2B) . Plasma 203 concentrations were higher in the β-CD combination groups than in self-assembly LC with 204 water. Diosgenin bioavailability was significantly higher after the oral administration of GMO 205 LC with β-CD solution than after GMO LC with water. 206 207
Skin distribution of diosgenin 208
The distributions of diosgenin in skin were determined after the oral administration of 209 diosgenin or its LC and summarized in Figure 3 respectively. The content of diosgenin was significantly higher in the GMO LC with β-CD 213 solution groups than in the diosgenin suspension. 214
Discussion 215
We initially prepared diosgenin LCs and characterized their physical properties. 216
Self-assembly LCs and dispersed LCs were prepared and analyzed using SAXS and Zetasizer. 217
The SAXS data demonstrated that GMO and PHY, which dissolved diosgenin, formed 218 hexagonal and cubic phases, respectively, when mixed with equal volumes of water at room 219 
Conclusions 247
The aim of this study was to improve the bioavailability of diosgenin. We prepared 248 
